Kevin Dietsch/Getty Images News The White House plans to drop its $1.8B so-called “weaponization” fund that was meant to pay alleged victims of overzealous prosecutorial conduct by the U.S. Justice Department under his predecessor, according to a media report on Monday. The reversal came after President Donald Trump faced pushback from Republicans in the House and Senate. "It's dead for now," said...
Kevin Dietsch/Getty Images News The White House plans to drop its $1.8B so-called “weaponization” fund that was meant to pay alleged victims of overzealous prosecutorial conduct by the U.S. Justice Department under his predecessor, according to a media report on Monday. The reversal came after President Donald Trump faced pushback from Republicans in the House and Senate. "It's dead for now," said one senior administration official, Axios reported. Another senior official also told the news organization that the effort would be scuttled. The fund was the bulk of a settlement under which President Donald J. Trump would drop his $10B lawsuit against the Internal Revenue Service. Critics of the settlement said it created a “slush” fund that could be used to compensate those convicted for the assault on the Capitol on Jan. 6, 2021. Late on Friday, the Wall Street Journal , citing people familiar with the matter, reported that Trump's aides had discussed whether he should nix the fund in exchange for getting immigration enforcement funding passed this month. Dear readers: We recognize that politics often intersects with the financial news of the day, so we invite you to click here to join the separate political discussion. More on Markets and Politics Oil Gains On Apparent Lack Of Middle East Progress Jerome Powell: Fed credibility at risk if presidents can fire officials SEC proposes to rescind Biden-era climate-related disclosure rules Trump Brought An Army Of CEOs To Beijing For A Reason
Shares of Applied Optoelectronics (NASDAQ:AAOI) are up 20% in midday trading to around $190, snapping back hard from a Friday close of $158.41. The single-session pop lifts the stock’s year-to-date (YTD) 2026 gain to an impressive 439%. Meanwhile, Lumentum (NASDAQ:LITE) stock is up 7% to $914 and Coherent (NYSE:COHR) stock is roughly flat near $363. ... Applied Optoelectronics Is Up 439% in 2026: ...
Shares of Applied Optoelectronics (NASDAQ:AAOI) are up 20% in midday trading to around $190, snapping back hard from a Friday close of $158.41. The single-session pop lifts the stock’s year-to-date (YTD) 2026 gain to an impressive 439%. Meanwhile, Lumentum (NASDAQ:LITE) stock is up 7% to $914 and Coherent (NYSE:COHR) stock is roughly flat near $363. ... Applied Optoelectronics Is Up 439% in 2026: Is It Outperforming Other Optics Stocks Like Lumentum and Coherent?
Lean hog futures are mixed with contracts 55 cents higher to 75 cents lower. USDA’s national base hog price was reported at $93.83 on Monday morning, up $1.01 from the day prior. The CME Lean Hog Index was back up 48 cents on May 28 at $91.40. Managed money continues...
Lean hog futures are mixed with contracts 55 cents higher to 75 cents lower. USDA’s national base hog price was reported at $93.83 on Monday morning, up $1.01 from the day prior. The CME Lean Hog Index was back up 48 cents on May 28 at $91.40. Managed money continues...
Live cattle futures are up 65 cents to $1.80 at midday. Cash trade picked up last week to $255-258 across the country. Feeder cattle futures are $3.30 to $3.50 in the front months at midday. The CME Feeder Cattle Index was back up $3.77 on May 28 to $373.40. Late...
Live cattle futures are up 65 cents to $1.80 at midday. Cash trade picked up last week to $255-258 across the country. Feeder cattle futures are $3.30 to $3.50 in the front months at midday. The CME Feeder Cattle Index was back up $3.77 on May 28 to $373.40. Late...
Soybeans are down 3 to 8 cents across most contracts on Monday. The cmdtyView national average Cash Bean price was down 9 1/4 cents at $11.25 3/4. Soymeal futures are down $2.80 to $4, with Soy Oil futures 119 to 131 points higher. Export Inspections data showed 494,286 MT (18.16...
Soybeans are down 3 to 8 cents across most contracts on Monday. The cmdtyView national average Cash Bean price was down 9 1/4 cents at $11.25 3/4. Soymeal futures are down $2.80 to $4, with Soy Oil futures 119 to 131 points higher. Export Inspections data showed 494,286 MT (18.16...
For many Americans, the term CEO is interchangeable with owner. When they think of people like Tesla CEO Elon Musk, they think of him as the owner of the company. But Musk, and all chief executives, are employees of the companies they work for. They are the highest profile, most well-paid ...
For many Americans, the term CEO is interchangeable with owner. When they think of people like Tesla CEO Elon Musk, they think of him as the owner of the company. But Musk, and all chief executives, are employees of the companies they work for. They are the highest profile, most well-paid ...
Nvidia Corp (NASDAQ:NVDA, XETRA:NVD)’s latest announcements at its GTC Taipei event have reinforced the company's position in artificial intelligence infrastructure while expanding its reach into new computing markets, according to Bank of America, which maintained a 'Buy' rating and $350 price...
Nvidia Corp (NASDAQ:NVDA, XETRA:NVD)’s latest announcements at its GTC Taipei event have reinforced the company's position in artificial intelligence infrastructure while expanding its reach into new computing markets, according to Bank of America, which maintained a 'Buy' rating and $350 price...
patty_c/iStock Unreleased via Getty Images I wanted to take a look at Petco Health and Wellness Company, Inc. ( WOOF ), which I had been a loyal customer of for a few years before leaving the country where it is not available, ahead of its June 3rd earnings release to see if it would be a contender for a spot in my portfolio. It fits my diversification efforts away from anything AI, and its share ...
patty_c/iStock Unreleased via Getty Images I wanted to take a look at Petco Health and Wellness Company, Inc. ( WOOF ), which I had been a loyal customer of for a few years before leaving the country where it is not available, ahead of its June 3rd earnings release to see if it would be a contender for a spot in my portfolio. It fits my diversification efforts away from anything AI, and its share price is down over 80% since the IPO; however, there is still a lot of work to be done before I would consider it a Buy. The company Petco is a specialty retailer and pet health and wellness company that sells pet food, supplies, and services like grooming and vet care. The business model is to sell pet food, treats, litter, toys, carriers, and cages and offer grooming services, training, and vet visits. It currently operates in over 1300 locations across the U.S., Mexico, and Puerto Rico, and it has an e-commerce component through the website or the Petco app. Financials Let’s take a look at the company’s latest performance for FY2025 , starting with the top line. Net sales came in at around $5.96B for the year, down around 2.5% y/y. Products came in at $4.94B, down 3.5% y/y, while services softened the blow slightly as they grew 2.6% to $1.025B. The company’s top line continues to underperform, but it is not falling off a cliff. Looking at the company’s profitability, we can see a little bit of an improvement over the last year, even as its top line continues to come in soft. Gross margins for the year improved by around 70bps to 38.7%. Product cost of sales drove the improvements here as they declined around 110bps y/y, while services cost of sales increased 40bps. Due to this slight improvement in cost of sales as well as less spent on SG&A, operating margins improved significantly by 200bps to 2.1%, while its adjusted EBITDA for the year came in at $408m, or 6.8% of sales. That’s a 130bps improvement over the last year. Going over the company’s financial position , we ...
ImmunityBio在2026年美国临床肿瘤学会年会上公布了两项壁报和一篇在线摘要，展示了其IL-15受体激动剂免疫疗法ANKTIVA在非小细胞肺癌和膀胱癌领域的最新临床数据。 在非小细胞肺癌方面，两项随机III期试验数据值得关注。第一项为ResQ201A试验，评估ANKTIVA联合替雷利珠单抗及多西他赛，对比多西他赛单药治疗免疫检查点抑制剂耐药的晚期或转移性非小细胞肺癌患者的疗效。第二项为QUILT-2.023试验，评估ANKTIVA联合检查点抑制剂作为一线治疗方案在非小细胞肺癌患者中的疗效。 针对卡介苗无应答的非肌层浸润性膀胱癌，ImmunityBio公布了一项匹配调整间接比较分析结果，对比ANKTIVA联合BCG与帕博利珠单抗的疗效。该分析基于QUILT-3.032试验与帕博利珠单抗单药治疗数据的间接比较。 此前在2026年美国泌尿外科协会年会上，ImmunityBio已公布了ANKTIVA+BCG相对于其他两种FDA批准疗法的间接比较结果。数据显示：与nadofaragene firadenovec-vncg相比，ANKTIVA+BCG治疗的患者在任何时间点达到完全缓解的可能性是其两倍（69.7% vs 53.4%），中位完全缓解持续时间超过两倍（22.1个月 vs 9.7个月），并将膀胱切除风险降低60%；与TAR-200相比，ANKTIVA+BCG在12个月时完全缓解率数值更高（49.2% vs 45.9%），且任何级别治疗相关不良事件显著更少（61.7% vs 83.5%）。 ImmunityBio创始人、执行董事长兼全球首席科学与医学官Patrick Soon-Shiong博士表示：“ASCO提供了一个重要机会，分享新兴的临床和转化数据，这些数据正不断加深我们对基于ANKTIVA的免疫疗法如何恢复免疫功能的理解。” 值得注意的是，ImmunityBio股价在过去一年表现强劲，年初至今累计上涨约280%，市值约76亿美元。 责任编辑：张俊 SF065